Navigation Links
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
Date:4/30/2008

006, ISTA licensed from Senju the exclusive North American rights to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to bringing a new product to market every 12 to 18 months, completing the preliminary analysis of the data from the Bepreve ocular safety study in the second quarter of 2008, filing the Bepreve NDA with the FDA in the second half of 2008, and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementat
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
2. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Researchers from the North American Menopause Society (NAMS) found ... too high, 1 putting women at risk for ... close to menopause are commonly told to take supplements ... as osteoporosis, to which they are particularly prone. ... calcium they typically get through their food sources before ...
(Date:7/23/2014)... 2014 This September leading clinicians in orthodontics ... Vegas for DOCtalk 2014 —a "Dynamic ... thinker and private practitioner Dr. David Sarver , ... discuss clinical and practice management efficiency and high quality ... opportunity to welcome fresh thinking and join a community ...
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... a pharmaceutical company dedicated to improving healthcare through ... range of prescription and over-the-counter ("OTC") products, today ... Mr. Tony Liu and Chief Financial Officer, Ms. ...
... that a new market research report is available in ... in China http://www.reportlinker.com/p0363587/The-Top-10-CMOs-in-China.html ... and future outlook of CMO industry in China. It ... the top 10 CMOs. Other leading players are also ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds The Top 10 CMOs in China 2
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... Adipic acid is an intermediate chemical ... plastic, often referred to as engineering thermoplastics. These ... the monomers employed. Due to the high production ... increasing number of developing countries, the Asia-Pacific region ... by Europe and North America. Adipic acid in ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Children and teens who lose ... death in adulthood, a new study suggests. People who ... 50 percent greater risk of death during the study period ... parent, according to the report. Although the study found ... risk of premature death, it wasn,t designed to prove cause-and-effect. ...
(Date:7/23/2014)... ill patients arriving at the emergency department, the ... amnesia for rapid, life-saving intubation, despite decades-old studies ... results of a systematic review of 10 recent ... a "wonder drug" are published online in ... of Ketamine on Intracranial and Cerebral Perfusion Pressure ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... Deanne Thompson of the Orange County Health Care Agency has confirmed ... have contributed to the outbreak of a lung fluke parasite infection ... every one of these eight -- or any of them -- ... month only four people had been confirmed as being infected, but ...
... UNAIDS, the available funding for 2006 was $8.9 billion ... the national governments to find strategies to maximize the ... The conference will attempt to address the issue through ... conference, which will be held Wednesday, September 13 to ...
... their plans to go into a partnership with NASPGHAN ... ,International publisher John Wiley & Sons, Inc., had ... a new agreement with the North American Society for ... Association for the Study of Liver Diseases (AASLD). ...
... According to a recent study by psychologists at the University ... more acceptable to the learned than the// poorly educated. ... BA Festival of Science on Setpember 5. ,If ... the UK "design into" their kids, this was studied by ...
... People in New Zealand have found a unique ... pregnancy is a vice. Church bells rang in ... ,This ritual is followed worldwide on the ... against raise awareness of Fetal Alcohol Syndrome. Organizer ...
... below the age of five will be administered anti-polio ... reported //no polio case for the second consecutive year. ... Delhi Chief Minister Sheila Dikshit Saturday said the state ... spreading of the virus from neighbouring Uttar Pradesh. ...
Cached Medicine News:Health News:International Conference on The Costs And Benefits of HIV/AIDS Interventions in Developing Countries to be hosted by Harvard 2Health News:Designer babies 2Health News:1.8 mn Delhi Children to Receive Anti-polio Drops 2
... injectable low osmolar, nonionic, contrast media ... biologically inert when injected intra-arterially. Each ... of ioversol, 3.6 mg of tromethamine ... of edetate calcium disodium as a ...
... is a non-ionic monomeric contrast medium for ... and children. After a decade of clinical ... examinations, IMAGOPAQUE has proven to be a ... hundreds of radiology departments.Results from large multicentre ...
... ProHance® (gadoteridol) is a contrast medium ... form of a sterile, apyrogenic solution for ... contrast enhancement of the brain, spine and ... with unenhanced MRI) of lesions with abnormal ...
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
Medicine Products: